Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency

Abstract excerpt

The antidiabetic drug metformin efficiently circumvents the dilemma that in reducing the tumourigenicity of stem cells, their essence, specifically their pluripotency, must also be sacrificed. Metformin prevents the occurrence or drastically reduces the size and weight of teratoma-like masses after the transplantation of induced pluripotent stem (iPS) cells into immunodeficient mice. Yet, iPS cells implanted into...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Pancreatic function and diabetes
• Share to Pluripotent Stem Cells Research
• Share to Renal and related cancers